Brendan D. Curti - Concepedia

Author

Brendan D. Curti

Providence Portland Medical Center ORCID

Also Known As

A Agostoni, B CURTI, B Curti, B D Curti, B. Curti, B. D. Curti, B.D. Curti, Brendan Curti, Brendan D Curti, Brendan D. Curti

403

Publications

15.7K

Citations

H-Index

Concepts

All Affiliations

Providence Portland Medical Center The University of Texas MD Anderson Cancer Center Memorial Sloan Kettering Cancer Center Moffitt Cancer Center Huntsman Cancer Institute

About

Brendan D. Curti is an author at Providence Portland Medical Center specializing in medicine, immunology, and immunotherapy.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	24	47	2.2K
2	Health Sciences	8	8	415
3	Natural Sciences	1	1	61
4	Social Sciences	1	1	49
5	Allergy	1	1	49

Brendan D. Curti

119

Publications

13.6K

Citations

H-Index

Page 1

	Year	Citations
Talimogene Laherparepvec Improves Durable Response Rate in Patients With Advanced Melanoma Robert H.I. Andtbacka, Howard L. Kaufman, Frances A. Collichio, Journal of Clinical Oncology	2015	2.5K
Sunitinib in Patients With Metastatic Renal Cell Carcinoma Robert J. Motzer, Brian I. Rini, Ronald M. Bukowski, JAMA	2006	1.2K
gp100 Peptide Vaccine and Interleukin-2 in Patients with Advanced Melanoma Douglas J. Schwartzentruber, David H. Lawson, Jon Richards, New England Journal of Medicine	2011	878
Overall Survival Benefit with Tebentafusp in Metastatic Uveal Melanoma Paul Nathan, Jessica C. Hassel, Piotr Rutkowski, New England Journal of Medicine	2021	806
OX40 Is a Potent Immune-Stimulating Target in Late-Stage Cancer Patients Brendan D. Curti, Magdalena Kovacsovics-Bankowski, Nicholas P. Morris, Cancer Research	2013	502
Combination Dabrafenib and Trametinib Versus Combination Nivolumab and Ipilimumab for Patients With Advanced <i>BRAF</i>-Mutant Melanoma: The DREAMseq Trial—ECOG-ACRIN EA6134 Michael B. Atkins, Sandra J. Lee, Bartosz Chmielowski, Journal of Clinical Oncology	2022	402
Lifileucel, a Tumor-Infiltrating Lymphocyte Therapy, in Metastatic Melanoma Amod A. Sarnaik, Omid Hamid, Nikhil I. Khushalani, Journal of Clinical Oncology	2021	373
Phase 1 Study of Stereotactic Body Radiotherapy and Interleukin-2—Tumor and Immunological Responses Steven K. Seung, Brendan D. Curti, Marka R. Crittenden, Science Translational Medicine	2012	302
Immunomodulatory Activity of Nivolumab in Metastatic Renal Cell Carcinoma Toni K. Choueiri, Mayer Fishman, Bernard Escudier, Clinical Cancer Research	2016	290
Safety and efficacy results of the advanced renal cell carcinoma sorafenib expanded access program in North America Walter M. Stadler, Robert A. Figlin, David F. McDermott, Cancer	2010	253

Page 1